BioCentury
ARTICLE | Clinical News

Vical starts Phase II with MuStDO 5

August 22, 2000 7:00 AM UTC

VICL and partners Aventis (AVE) and the U.S. Navy began a Phase II trial of MuStDO 5, a DNA vaccine designed to prevent infection by the malaria parasite Plasmodium falciparum. The dose escalation tri...